• Something wrong with this record ?

Clinical Development and Commercialization of Advanced Therapy Medicinal Products in the European Union: How Are the Product Pipeline and Regulatory Framework Evolving

T. Boráň, M. Menezes-Ferreira, I. Reischl, P. Celis, N. Ferry, B. Gänsbacher, H. Krafft, M. Lipucci di Paola, D. Sladowski, P. Salmikangas,

. 2017 ; 28 (3) : 126-135. [pub] 20170516

Language English Country United States

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc18010558

The research and development of advanced therapy medicinal products (ATMPs) has been active in Europe and worldwide during recent years. Yet, the number of licensed products remains low. The main expected legal change in the near future in the European Union (EU) concerns the regulation on clinical trials (536/2014), which will come into force in 2018. With this new framework, a more harmonized and swift process for approval of clinical trials is anticipated, which is expected to support the entry of new innovations into the EU market. A survey on ATMPs in clinical trials during 2010-2015 in the EU was conducted in order to study the trends of ATMP development since the earlier survey published in 2012. According to the results, the number of clinical trials using ATMPs is slowly increasing in the EU. Yet, the focus is still in early development, and the projects are mainly carried out by small and medium-sized enterprises, academia, and hospitals. Oncology is the main area of clinical development. Yet, the balance between cell-based products and gene therapy medicinal products in this area may be changing in the future due to the new T-cell technologies. Many limitations and challenges are identified for ATMP development, requiring proportionate regulatory requirements. On the other hand, for such a novel field, the developers should be active in considering possible constraints and actively engage with authorities to look for solutions. This article provides up to-date information on forthcoming regulatory improvements and discusses the main challenges hampering the commercialization of ATMPs in the EU.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18010558
003      
CZ-PrNML
005      
20241126155614.0
007      
ta
008      
180404s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1089/humc.2016.193 $2 doi
035    __
$a (PubMed)28510497
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Boráň, Tomáš $u Státní üstav pro kontrolu léčiv, Prague, Czech Republic. $7 xx0326049
245    10
$a Clinical Development and Commercialization of Advanced Therapy Medicinal Products in the European Union: How Are the Product Pipeline and Regulatory Framework Evolving / $c T. Boráň, M. Menezes-Ferreira, I. Reischl, P. Celis, N. Ferry, B. Gänsbacher, H. Krafft, M. Lipucci di Paola, D. Sladowski, P. Salmikangas,
520    9_
$a The research and development of advanced therapy medicinal products (ATMPs) has been active in Europe and worldwide during recent years. Yet, the number of licensed products remains low. The main expected legal change in the near future in the European Union (EU) concerns the regulation on clinical trials (536/2014), which will come into force in 2018. With this new framework, a more harmonized and swift process for approval of clinical trials is anticipated, which is expected to support the entry of new innovations into the EU market. A survey on ATMPs in clinical trials during 2010-2015 in the EU was conducted in order to study the trends of ATMP development since the earlier survey published in 2012. According to the results, the number of clinical trials using ATMPs is slowly increasing in the EU. Yet, the focus is still in early development, and the projects are mainly carried out by small and medium-sized enterprises, academia, and hospitals. Oncology is the main area of clinical development. Yet, the balance between cell-based products and gene therapy medicinal products in this area may be changing in the future due to the new T-cell technologies. Many limitations and challenges are identified for ATMP development, requiring proportionate regulatory requirements. On the other hand, for such a novel field, the developers should be active in considering possible constraints and actively engage with authorities to look for solutions. This article provides up to-date information on forthcoming regulatory improvements and discusses the main challenges hampering the commercialization of ATMPs in the EU.
650    _2
$a biomedicínský výzkum $x ekonomika $x zákonodárství a právo $x normy $7 D035843
650    _2
$a klinické zkoušky jako téma $x ekonomika $x zákonodárství a právo $x normy $7 D002986
650    _2
$a farmaceutický průmysl $x ekonomika $x zákonodárství a právo $x normy $7 D004345
650    _2
$a Evropská unie $7 D005062
650    12
$a transfer technologií $7 D018581
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Menezes-Ferreira, Margarida $u Infarmed-National Authority of Medicines and Health Products, Lisbon, Portugal.
700    1_
$a Reischl, Ilona $u Austrian Medicines and Medical Devices Agency (AGES MEA), Vienna, Austria.
700    1_
$a Celis, Patrick $u European Medicines Agency (EMA), London, United Kingdom.
700    1_
$a Ferry, Nicolas $u Université Paris Descartes , Paris, France.
700    1_
$a Gänsbacher, Bernd $u Institute of Experimental Oncology and Therapeutics, Technical University of Munich , Munich, Germany.
700    1_
$a Krafft, Hartmut $u Paul-Ehrlich Institute , Langen, Germany.
700    1_
$a Lipucci di Paola, Michele $u European Organisation for Rare Diseases, Paris, France.
700    1_
$a Sladowski, Dariusz $u Medical University of Warsaw , Department of Transplantology and Central Tissue Bank, Warsaw, Poland.
700    1_
$a Salmikangas, Paula $u Finnish Medicines Agency, Helsinki, Finland .
773    0_
$w MED00195041 $t Human gene therapy. Clinical development $x 2324-8645 $g Roč. 28, č. 3 (2017), s. 126-135
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28510497 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20241126155610 $b ABA008
999    __
$a ok $b bmc $g 1288043 $s 1007370
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 28 $c 3 $d 126-135 $e 20170516 $i 2324-8645 $m Human gene therapy. Clinical development $n Hum Gene Ther Clin Dev $x MED00195041
LZP    __
$a Pubmed-20180404

Find record

Citation metrics

Archiving options